Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07243275 · ClinicalTrials.gov registry record · Phase 4
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
A Phase 4 study, sponsored by Indiana University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 260
- Enrollment target
NCT07243275 is a Phase 4 study that is actively recruiting participants, run by Indiana University. The registered enrollment target is 260 participants.
The verdict
NCT07243275, a Phase 4 study, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 260 participants
- Enrollment target
Study Summary
This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-inferior to MIEBO™ after one month of treatment, based on change in Ocular Surface Disease Index (OSDI) scores.
Interventions
- DRUG SYSTANE® PRO
- DRUG MIEBO™ (Perfluorohexyloctane, PFHO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07243275
The ClinicalTrials.gov registry entry for NCT07243275 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SYSTANE® PRO is the first listed.
NCT07243275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07243275 about?
NCT07243275 is a clinical study titled "SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease". This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-in...
What is the current status of trial NCT07243275?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 260 participants. The study started on 2026-02-18. Estimated completion is 2026-09-30.
What interventions are being tested in trial NCT07243275?
The interventions under investigation include: SYSTANE® PRO (DRUG), MIEBO™ (Perfluorohexyloctane, PFHO) (DRUG).
Who is sponsoring clinical trial NCT07243275?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.